Acorda Rises On Restructuring, ALXN Pauses COVID-19 Trial, SYBX On Watch
Acorda Rises On Restructuring, ALXN Pauses COVID-19 Trial, SYBX On Watch Read on. 1. Acorda Rises on Corporate Restructuring Shares of Acorda Therapeutics Inc. (ACOR) jumped over 44% on Wednesday, on news of the company agreeing to sell its INBRIJA manufacturing operations in Chelsea, Massachusetts to Catalent, Inc. (CTLT) for $80 million in cash. INBRIJA is a prescription medicine from Acorda Therapeutics indicated for use when needed with hypomobility or OFF episodes in adults with Parkinson's disease treated with regular carbidopa/levodopa medicine. The companies have also inked a long-ter...
Source: finanznachrichten.de